Literature DB >> 10806829

Effects of perindopril on vascular wall and left ventricular hypertrophy in rats with experimental hypertension.

J Tang1, Q Zhou, C Wu, Q Liang.   

Abstract

The model of hypertensive rat was established by using the method of abdominal aortic constriction, 33 male SD rats were randomly divided into 4 groups: group A (sham-operated rats serving as controls), group B (hypertensive rats serving as controls), group C (hypertensive rats subjected to low-dose perindopril treatment, 0.1 mg.kg-1/d) and group D (hypertensive rats receiving high-dose perindopril treatment, 1.5 mg.kg-1/d). The drug was administered by gavage for 4 weeks. At the end of the treatment, mean arterious pressure (MAP) was measured via catheter in the carotid artery. The heart was taken and weighed to calculate the ratio of left ventricular weight to body weight (LVW/BW). The ratio of medial mean thickness to mean diameter of lumen of aorta and superior mesenteric artery was calculated by morphometry. Concentration of angiotensin II (A II) in plasma and in aortic wall were determined by radioimmunoassay (PA II, AA II). Our results showed that both high-dose and low-dose perindopril may prevent hypertrophy of left ventricle and hypertrophy of the tunica media of superior mesenteric artery. In addition, high-dose perindopril may significantly inhibit hypertrophy of aortic media. The above effects of perindopril may be explained by inhibition on tissue renin-angiotensin system of both vascular wall and heart, but is not related to circulating A II (PA II).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10806829     DOI: 10.1007/bf02888471

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  7 in total

1.  Effects of drug treatment on human resistance arteriole morphology in essential hypertension: direct evidence for structural remodelling of resistance vessels.

Authors:  A M Heagerty; S J Bund; C Aalkjaer
Journal:  Lancet       Date:  1988-11-26       Impact factor: 79.321

2.  Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats.

Authors:  W Linz; B A Schölkens; D Ganten
Journal:  Clin Exp Hypertens A       Date:  1989

3.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

4.  Remodeling of the rat right and left ventricles in experimental hypertension.

Authors:  C G Brilla; R Pick; L B Tan; J S Janicki; K T Weber
Journal:  Circ Res       Date:  1990-12       Impact factor: 17.367

5.  Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats.

Authors:  G Olivetti; E Cigola; C Lagrasta; R Ricci; F Quaini; A Monopoli; E Ongini
Journal:  J Cardiovasc Pharmacol       Date:  1993-03       Impact factor: 3.105

Review 6.  Role of the cardiac renin-angiotensin system in hypertensive cardiac hypertrophy.

Authors:  Y A Lee; K Lindpaintner
Journal:  Eur Heart J       Date:  1993-11       Impact factor: 29.983

7.  Effects of 4 weeks of treatment with trandolapril on renal hypertension and cardiac and vascular hypertrophy in the rat.

Authors:  A Corbier; D Lecaque; J Secchi; B Depouez; G Hamon
Journal:  J Cardiovasc Pharmacol       Date:  1994       Impact factor: 3.105

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.